Literature DB >> 28986954

Role of CYP3A in Oral Contraceptives Clearance.

Nan Zhang1,2, Jihong Shon1, Myong-Jin Kim1, Chongwoo Yu1, Lei Zhang1, Shiew-Mei Huang1, LaiMing Lee1, Doanh Tran1, Li Li1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28986954      PMCID： PMC5944580          DOI： 10.1111/cts.12499

Source DB:  PubMed          Journal:  Clin Transl Sci        ISSN： 1752-8054            Impact factor:   4.689


× No keyword cloud information.
  57 in total

1.  The effects of rifampin and rifabutin on the pharmacokinetics and pharmacodynamics of a combination oral contraceptive.

Authors:  P Barditch-Crovo; C B Trapnell; E Ette; H A Zacur; J Coresh; L E Rocco; C W Hendrix; C Flexner
Journal:  Clin Pharmacol Ther       Date:  1999-04       Impact factor: 6.875

2.  In vitro OATP1B1 and OATP1B3 inhibition is associated with observations of benign clinical unconjugated hyperbilirubinemia.

Authors:  William J Chiou; Sonia M de Morais; Ryota Kikuchi; Richard L Voorman; Xiaofeng Li; Daniel A J Bow
Journal:  Xenobiotica       Date:  2013-07-25       Impact factor: 1.908

3.  Ring A oxidation of 17alpha-ethynylestradiol in man.

Authors:  W H Bolt; H Kappus; H M Bolt
Journal:  Horm Metab Res       Date:  1974-09       Impact factor: 2.936

4.  Excretion and stereoselective biotransformations of dl-, d- and l-norgestrel in women.

Authors:  S F Sisenwine; H B Kimmel; A L Liu; H W Ruelius
Journal:  Drug Metab Dispos       Date:  1975 May-Jun       Impact factor: 3.922

5.  Induction of ethinylestradiol and levonorgestrel metabolism by oxcarbazepine in healthy women.

Authors:  C Fattore; G Cipolla; G Gatti; G L Limido; Y Sturm; C Bernasconi; E Perucca
Journal:  Epilepsia       Date:  1999-06       Impact factor: 5.864

Review 6.  Metabolism of levonorgestrel, norethindrone, and structurally related contraceptive steroids.

Authors:  F Z Stanczyk; S Roy
Journal:  Contraception       Date:  1990-07       Impact factor: 3.375

7.  Effects of rifabutin and rifampicin on the pharmacokinetics of ethinylestradiol and norethindrone.

Authors:  M LeBel; E Masson; E Guilbert; D Colborn; F Paquet; S Allard; F Vallée; P K Narang
Journal:  J Clin Pharmacol       Date:  1998-11       Impact factor: 3.126

Review 8.  All progestins are not created equal.

Authors:  Frank Z Stanczyk
Journal:  Steroids       Date:  2003-11       Impact factor: 2.668

9.  Pharmacokinetic interaction between bosentan and the oral contraceptives norethisterone and ethinyl estradiol.

Authors:  P L M van Giersbergen; A Halabi; J Dingemanse
Journal:  Int J Clin Pharmacol Ther       Date:  2006-03       Impact factor: 1.366

10.  Regulation of aldo-keto reductases in human diseases.

Authors:  Wei-Dong Chen; Yanqiao Zhang
Journal:  Front Pharmacol       Date:  2012-03-09       Impact factor: 5.810
View more
  14 in total

1.  Drug-Drug Interaction Studies of Elagolix with Oral and Transdermal Low-Dose Hormonal Add-Back Therapy.

Authors:  Ahmed Nader; Nael M Mostafa; Farah Ali; Mohamad Shebley
Journal:  Clin Pharmacokinet       Date:  2021-01       Impact factor: 6.447

2.  Effects of ritonavir-boosted protease inhibitors on combined oral contraceptive pharmacokinetics and pharmacodynamics in HIV-positive women.

Authors:  Teresa Barcellos; Melissa Natavio; Frank Z Stanczyk; Dandan Luo; William J Jusko; Nicole M Bender
Journal:  Contraception       Date:  2019-06-10       Impact factor: 3.375

3.  Influence of Genetic Variants on Steady-State Etonogestrel Concentrations Among Contraceptive Implant Users.

Authors:  Aaron Lazorwitz; Christina L Aquilante; Kris Oreschak; Jeanelle Sheeder; Maryam Guiahi; Stephanie Teal
Journal:  Obstet Gynecol       Date:  2019-04       Impact factor: 7.661

4.  Etonogestrel contraceptive implant failure in a woman taking rifampin: a case report.

Authors:  Tesfaye H Tufa; Abraham Fessehaye; Ferid A Abubeker
Journal:  Contracept Reprod Med       Date:  2022-05-05

5.  Antiretroviral therapy and vaginally administered contraceptive hormones: a three-arm, pharmacokinetic study.

Authors:  Kimberly K Scarsi; Yoninah S Cramer; Susan L Rosenkranz; Francesca Aweeka; Baiba Berzins; Robert W Coombs; Kristine Coughlin; Laura E Moran; Carmen D Zorrilla; Victor Akelo; Mariam Aziz; Ruth K Friedman; David Gingrich; Shobha Swaminathan; Catherine Godfrey; Susan E Cohn
Journal:  Lancet HIV       Date:  2019-09       Impact factor: 12.767

6.  The Effects of Weak and Strong CYP3A Induction by Rifampicin on the Pharmacokinetics of Five Progestins and Ethinylestradiol Compared to Midazolam.

Authors:  Herbert Wiesinger; Stefan Klein; Antje Rottmann; Bettina Nowotny; Kai Riecke; Isabella Gashaw; Margarete Brudny-Klöppel; Robert Fricke; Joachim Höchel; Christian Friedrich
Journal:  Clin Pharmacol Ther       Date:  2020-05-11       Impact factor: 6.875

7.  Pharmacokinetic and Pharmacodynamic Profiles of Ethinylestradiol/Norgestimate Combination or Norethindrone upon Coadministration with Elagolix 150 mg Once Daily in Healthy Premenopausal Women.

Authors:  Robert A Feldman; Yi-Lin Chiu; Cheri E Klein; Juki Ng
Journal:  Clin Pharmacokinet       Date:  2021-03-22       Impact factor: 6.447

8.  Evaluation of the potential for pharmacokinetic interaction between tirabrutinib and levonorgestrel/ethinyl estradiol in healthy female volunteers.

Authors:  Ganesh Cherala; Cara Nelson; Ying Guo; Anubhav Mathur; Thomas Tarnowski; Ahmed A Othman
Journal:  Clin Transl Sci       Date:  2022-03-28       Impact factor: 4.438

9.  Quantitative Assessment of Levonorgestrel Binding Partner Interplay and Drug-Drug Interactions Using Physiologically Based Pharmacokinetic Modeling.

Authors:  Brian Cicali; Karthik Lingineni; Rodrigo Cristofoletti; Thomas Wendl; Joachim Hoechel; Herbert Wiesinger; Ayyappa Chaturvedula; Valvanera Vozmediano; Stephan Schmidt
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2020-12-13

10.  Effects of Lemborexant on the Pharmacokinetics of Oral Contraceptives: Results From a Phase 1 Drug-Drug Interaction Study in Healthy Females.

Authors:  Ishani Landry; Jagadeesh Aluri; Nancy Hall; Gleb Filippov; Satish Dayal; Margaret Moline; Larisa Reyderman
Journal:  Clin Pharmacol Drug Dev       Date:  2021-06-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.